Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


The Impact of Clinical Trials in Tennessee


 
Sen. Mark Green, MD, discusses the importance of local clinical trials and biopharmaceutical research in Tennessee. Pictured (L-R) James and Josi Felts, Dr. Paul Newhouse, Dr. Jeffrey Conn, and Sen. Mark Green.

On Jan. 23, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 945 active clinical trials in the Tennessee. Additionally, the report said the life science industry supports 52,000 jobs and contributes $11.7 billion to the state's economy.

"Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in Tennessee," was released at an event held at the Cordell Hull Building, which featured a panel discussion by Vanderbilt University Medical Center biotech researchers, Tennessee State Senator Mark Green, MD, (R-22), and a local Alzheimer's disease patient and clinical trial participant.

"Clinical trials offer patients novel medical treatments while also allowing biopharma research organizations to innovate and grow," said Green, founder of Align MD. "Across the state - and particularly here in Nashville - the healthcare industry has had a profound impact on our economy."

In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations. In Tennessee, active trials are studying treatment options for more than 20 disease sites or types, with cancer trials leading the way by a large margin. Of the 945 open clinical trials involving the biopharmaceutical research industry, Vanderbilt is collaborating on more than 245 of them. In addition, the report cites Meharry Medical College, Sarah Cannon, Clinical Research Associates, Tennessee Clinical Research Center, Tennessee Oncology, Tennessee Retina, and all of the city's major hospitals and health systems as active participants in Nashville.

"Many top universities call Tennessee home and are centers of innovation," said Jeffrey Conn, PhD, director of the Vanderbilt Center for Neuroscience Drug Discovery. "Maintaining strong partnerships between medical universities and life science companies allows us to foster developments right here in Tennessee that can then help save lives far beyond our state lines."

On average, it takes approximately a decade for new medicines to go through the FDA approval process, and only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted more than 6,100 clinical trials in Tennessee.

The complete report is available online at NashvilleMedicalNews.com

WEB:

Research in Your Backyard Report

 
Share:

Related Articles:


Recent Articles

AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association

Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.

Read More

Tennessee Sees Fewer Infant Deaths In 2018

Infant Mortality Data Dashboard Now Available

Read More

Amedisys Expanding Commitment to End-of-Life Care for Veterans

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Read More

AMA Applauds Relief from Documentation Burden in New Medicare Rule

Many physicians will have reduced documentation beginning in 2021

Read More

Oncology Innovation in Nashville

From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.

Read More

Critical Insights into Nashville Health

For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.

Read More

Physician Spotlight: Leading with Compassion

Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.

Read More

The Oncology Care Model Value Proposition

The American Journal of Managed Care® hosts meetings across the country to help oncology practices understand and navigate the value-based care landscape at the intersection of quality and efficiency.

Read More

Tennessee Falling Short on Cancer-Fighting Public Policies

A 2019 ACS CAN report shows the state is falling short on public policies to fight cancer.

Read More

ONcology Rounds

Middle Tennessee's robust oncology programs are tackling cancer on numerous fronts.

Read More

Email Print
 
 

 

 


Tags:
Biopharmaceutical Research, Clinical Trials, Jeffrey Conn, Life Sciences, Mark Green, Pharmaceutical Research and Manufacturers of America, Pharmaceuticals, PhRMA, Research in Your Backyard, Vanderbilt
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: